TEVA Form 144: Insider sold 115,468 shares

Teva Pharmaceutical Industries reports an insider Form 144 disclosing a sale of ordinary shares and upcoming compensation vesting.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries reports an insider Form 144 disclosing a sale of ordinary shares and upcoming compensation vesting. The filing shows 115,468 ordinary shares sold by Daniell Richard on 12/09/2025 for $3,311,131.04. The filing also lists compensation awards scheduled to vest on 03/03/2026: a Performance Share Unit award of 141,478 shares, Restricted Share Units of 24,900 shares, and Restricted Share Units (retention) of 37,350 shares.

Insights

Insider Transactions Specialist

Form 144 shows a reported sale of $3.31M and upcoming vested compensation on 03/03/2026.

The filing records 115,468 ordinary shares sold by Daniell Richard on 12/09/2025 for $3,311,131.04. This is a reported disposition under the securities transaction reporting rules.

The filing also lists compensation awards scheduled to vest on 03/03/2026: 141,478 PSUs, 24,900 RSUs, and 37,350 RSU retention shares. These vesting awards are context for future potential transactions; timing and any subsequent transactions will appear in later filings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TEVA's Form 144 disclose about insider sales?

It disclosed a sale of 115,468 ordinary shares for $3,311,131.04 by Daniell Richard on 12/09/2025. The filing lists the transaction details including share count and gross proceeds as reported in the Form 144 excerpt.

Does the filing show any upcoming vesting awards at TEVA (symbol TEVA)?

Yes. The filing lists awards scheduled to vest on 03/03/2026: a Performance Share Unit award of 141,478 shares, Restricted Share Units of 24,900 shares, and RSU retention of 37,350 shares.

Who reported the sale in the TEVA Form 144 and when was the sale dated?

The sale was reported for Daniell Richard, with the shares sold dated 12/09/2025. The filing entry shows the reporter's name and the transaction details included in the Form 144 excerpt.

Do the listed vesting awards in the Form 144 equal amounts being registered or sold now?

No. The filing lists compensation awards scheduled to vest on 03/03/2026 as separate items. Those awards are described with their vesting dates and share counts and are context for potential future transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 05:13 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001726096
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Daniell Richard
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP EUROPEAN COMMERCIAL

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	128985	4173941.70	1149812898	03/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/03/2023	PERFORMANCE SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			141478	03/03/2026	COMPENSATION
ORDINARY SHARES	03/03/2023	RESTRICTED SHARE UNIT AWARD VESTING EM	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			24900	03/03/2026	COMPENSATION
ORDINARY SHARES	03/03/2023	RESTRICTED SHARE UNIT AWARD VESTING EM RETENTION	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			37350	03/03/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniell Richard 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	12/09/2025	115468	3311131.04

144: Remarks and Signature

Remarks	SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES. THESE TRANSACTIONS WERE PART OF AN ESTABLISHED 10B51 PLAN ADOPTED ON NOVEMBER 2025
Date of Notice	03/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)